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ABSTRACT: Various mechanisms for regulated cell death
include the formation of oxidative mediators such as lipid
peroxides and nitric oxide (NO). In this respect, 15-
lipoxygenase-1 (15-LOX-1) is a key enzyme that catalyzes
the formation of lipid peroxides. The actions of these
peroxides are interconnected with nuclear factor-κB signaling
and NO production. Inhibition of 15-LOX-1 holds promise to
interfere with regulated cell death in inﬂammatory conditions. In this study, a novel potent 15-LOX-1 inhibitor, 9c (i472), was
developed and structure−activity relationships were explored. In vitro, this inhibitor protected cells from lipopolysaccharide-
induced cell death, inhibiting NO formation and lipid peroxidation. Thus, we provide a novel 15-LOX-1 inhibitor that inhibits
cellular NO production and lipid peroxidation, which set the stage for further exploration of these mechanisms.
1. INTRODUCTION
Over recent years, an increasing number of mechanisms for
regulated cell death have been identiﬁed and versatile roles in
numerous diseases were proposed.1 Cell death via a mechanism
other than apoptosis leads to plasma membrane rupture and
release of the cellular content, thus providing damage-associated
molecular patterns that can induce an autoampliﬁcation loop of
regulated cell death and inﬂammation. Such ampliﬁcation loops
are expected to play key roles in diseases such as acute lung
injury and acute respiratory distress syndrome.2 Understanding
the underlying mechanisms to develop small-molecule inhib-
itors to interfere with cell death holds promise for therapeutic
control of these disorders.
The discovery of multiple types of cell death provides new
challenges to identify the molecular mechanisms involved. One
mechanism of nonapoptotic cell death is pyroptosis in which
macrophages die by excessive stimulation of Toll-like receptors
and activation of the nuclear factor-κB (NF-κB) pathway by, for
example, lipopolysaccharides (LPS).2−6 Normally, pyroptosis is
a mechanism to protect multicellular organisms from invading
pathogens, such as microbial infections. However, under
pathogenic conditions, pyroptosis can be involved in the onset
of chronic inﬂammation. Another mechanism for nonapoptotic
cell death is ferroptosis, which is a process in which excessive
levels of lipid peroxides cause cell death. It is anticipated that
lipoxygenases (LOXs) play key roles in ferroptosis by catalyzing
lipid peroxidation.2,7 The identiﬁcation of pyroptosis, ferropto-
sis, and other mechanisms for regulated cell death raises the
question how these mechanisms can be exploited for drug
discovery.
Although distinct mechanisms for regulated cell death were
described, the mechanisms involved are often closely related and
crosstalk exists. In this study, we aim to address the crosstalk
between macrophage cell death upon LPS stimulation and the
enzymatic activity of 15-lipoxygenase-1 (15-LOX-1) as a
regulator of cellular lipid peroxidation (Figure 1).8 Activation
of the NF-κB pathway results in transcription of downstream
genes, such as inducible nitric oxide synthase (iNOS), that plays
a critical role in inﬂammatory responses.9 iNOS catalyzes the
formation of NO radicals that play key roles in many
physiological processes.10 On the other hand, excessive NO
production can lead to the formation of reactive nitrogen species
(RNOS), which induces cell death and tissue damage.11
Reactive oxygen species (ROS) such as lipid peroxides have
been shown to augment LPS-mediated NF-κB activation and
thus increase expression of NF-κB target genes,8,12 which
represents a mechanism of crosstalk between lipid peroxidation
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and NF-κB activation. 15-LOX-1 is a nonheme iron-containing
enzyme producing lipid peroxides from polyunsaturated fatty
acids, such as arachidonic acid (AA) and linoleic acid (LA).13−15
15-LOX-1 oxidizes either AA, to form the corresponding 15-
hydroxyeicosatetraenoic acid, or LA, to form the corresponding
13-hydroperoxyoctadecadienoic acid (13-HpODE).16,17 Apart
from these hydroperoxy fatty acids, lipoxins are also derived
from the 15-LOXs pathway and play a role as anti-inﬂammatory
mediators.18 On the other hand, the 15-LOXmetabolites eoxins
are proposed to be a family of proinﬂammatory eicosanoids.19
Altogether, lipid peroxides can be converted further into distinct
lipid signaling molecules that have key regulatory roles in
immune responses20−22 and numerous diseases.23 Importantly,
if the production of lipid peroxides is not balanced by the cellular
antioxidant system, this can result in ferroptotic cell death and in
enhanced activation of the NF-κB pathway, thus providing
synergistic crosstalk between two mechanisms of regulated cell
death.24 Thus, 15-LOX-1 is a key enzyme in oxidative stress and
regulated cell death in numerous diseases.13,25,26
For 15-LOX-1, roles have been described in diseases such as
asthma,14 stroke,15 atherogenesis,2 diabetes,16,17 cancer,20,21
Alzheimer’s disease,22,23 and Parkinson’s disease.25 This
triggered the interest in the development of 15-LOX-1 inhibitors
for drug discovery. In an early phase, indole-based inhibitors,
PD-146176, were identiﬁed as r-12/15-LOX inhibitors with a
half-maximal inhibitory concentration (IC50) value of 3.81 μM
(Figure 2).27 This stimulated eﬀorts to develop inhibitors with
an indolyl core (Figure 2). More researchers reported the
discovery of indole-based or indole-like 15-LOX-1 inhibitors,
371 and Haydi-4b (with IC50 values of 0.006 and 3.84 μM,
respectively).28,29 Our group previously discovered 15-LOX-1
inhibitor Eleftheriadis-14d, which also contains an indole core
and demonstrates good potency (IC50 = 90 nM).
30 Further-
more, a 1,3-oxazole-based compound (ML351),31 a purine-
based compound (Anders-6b),32 and pyrrole-based compound
(21B10)33 were identiﬁed as 15-LOX-1 inhibitors as well
(Figure 1). These inhibitors proved to be eﬀective in various
disease models, thus indicating the potential of 15-LOX-1
inhibitors for drug discovery.
Complementary to development of inhibitors, eﬀorts were
made to engineer 15-LOX-1 substrates for detection of enzyme
activity. We developed activity-based probe N144 as a chemical
reporter for lipoxygenase activity in cell lysates and tissue
samples.34 Another study employed the omega-alkynyl fatty acid
(aAA) to identify the intracellular targets of 12/15-LOX-
generated lipid-derived electrophiles.35 This sets the stage for
the development of potent 15-LOX-1 inhibitors and to study
their cellular activity.
In this study, we investigated novel substitutions of the indole
core and investigated the structure−activity relationships
(SARs) for 15-LOX-1 inhibition. For the most potent inhibitor,
the eﬀects on cellular 15-LOX-1 inhibition, the eﬀects on
formation of reactive oxygen species (ROS), and regulated cell
Figure 1. Several mechanisms of lipopolysaccharide (LPS) signaling in
macrophages are connected to cell death. LPS-mediated activation of
the NF-κB pathway results in the overexpression of inducible nitric
oxide synthase (iNOS). This leads to the production of nitric oxide
(NO) and reactive nitrogen species (RNOS), which are involved in cell
death. In the 15-LOX-1 pathway, 13-hydroperoxyoctadecadienoic acid
(13-HpODE), the metabolite of 15-LOX-1 activity, can also induce cell
death. Both mechanisms act in concert, and crosstalk exists.
Figure 2. Examples of previously reported 15-LOX-1 inhibitors and chemical tools to study lipoxygenase activity. (A) Indole-based 15-LOX-1
inhibitor and inhibitors based on other nitrogen-containing heterocycles. (B) Substrate-based chemical tools to study lipoxygenase activity in cell-
based systems.
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death were investigated on RAW 264.7 macrophages to provide
insight into the cellular potency of this type of inhibitors.
2. RESULTS AND DISCUSSION
2.1. Chemistry. Scheme 1 presents the general methodology
for the synthesis of compounds 5a and 5b. The synthesis started
with the assembly of ethyl 6-chloro-1H-indole-2-carboxylate (1)
and the corresponding aldehyde (2) using known literature
procedures.30,36 Subsequently, the 2-formyl functionality of the
aldehyde 2 was oxidized into its corresponding carboxylic acid
(3) via Pinnick oxidation using sodium chlorite (NaClO2),
giving a yield of 78%. Attempts to use KMnO4 or Tollens’
reagent did not provide the desired product. Finally, the amide
bonds in products 5a and 5b were generated using 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDCI) and N-hydroxy-
benzotriazole (HOBt) as coupling reagents, giving yields of
about 85%.
Compounds 9a−j were synthesized using procedures as
shown in Scheme 2. As a ﬁrst step, the 2-formyl functionality of
aldehyde 2 was employed for the Wittig reaction with (tert-
Scheme 1. Synthetic Route to Compounds 5a and 5ba
aReagents and conditions: (a) POCl3, dimethylformamide (DMF), 60 °C, 48 h; (b) NaClO2, t-BuOH, 50 °C, 4 h; (c) amine (4a and 4b), EDCI,
HOBt, Et3N, dichloromethane (DCM), room temperature (r.t.), 4 h.
Scheme 2. Synthetic Route to Compounds 9a−ja
aReagents and conditions: (d) (tert-butoxycarbonylmethylene)triphenylphosphorane, EtOH, reﬂux, 2 h; (e) TFA, DCM, r.t., overnight; (f) amine
(8a−j), EDCI, HOBt, Et3N, DCM, r.t., 4 h.
Scheme 3. Synthetic Route to Compounds 12a−g and 13a
aReagents and conditions: (g) amine (11a−g), EDCI, HOBt, Et3N, DCM, r.t., 4 h; (h) dimethylamine, formaldehyde, acetic acid, MeOH, reﬂux, 4
h.
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butoxycarbonylmethylene)triphenylphosphorane to provide the
α,β-unsaturated ester 6. Initially, attempts were made to obtain
compound 7 by reﬂuxing aldehyde 2 with the Wittig reagent in
toluene overnight. However, this provided compound 6 as a
mixture of E- and Z-isomers (E/Z = approximately 9/1).37
Changing the solvent from toluene to ethanol at 80 °C enabled
the reaction to ﬁnish in 2 h with the E-alkene as the major
product that could be isolated in a yield of 70% after puriﬁcation.
The E- and Z-isomer could be distinguished by their J values of
16.0 and 7.0 Hz, respectively. Finally, intermediate 7 was
converted into the amides 9a−j by removal of the tert-butyl
protecting group using triﬂuoroacetic acid (TFA) treatment and
subsequent coupling of the corresponding amines using 1-ethyl-
3-(3-dimethylaminopropyl)carbodiimide (EDCI) and N-hy-
droxybenzotriazole (HOBt) as coupling reagents in yields
between 80 and 90% over two steps.
Products 12a−g were produced starting from compound 10
as shown in Scheme 3. The carboxylic acid 10 was coupled to
amines 11a−g using EDCI and HOBt as coupling reagents,
which gives the desired products in 80−90% yield. Afterward,
compound 13 was obtained from compound 12c using a
Mannich reaction with dimethylamine, formaldehyde, and
acetic acid to provide the desired product in a yield of 93%.
As shown in Scheme 4, compounds 14−17 were obtained from
the corresponding 2-carboxy ethyl indoles (9c, Eleftheriadis-
14d and Eleftheriadis-14e) over two steps in a similar way as for
12a−g in a high yield (80−90%).
2.2. Structure−Activity Relationships. Inhibition of 15-
LOX-1 enzyme activity was performed using an activity assay as
described previously by us.30,33,38 The activity of 15-LOX-1 was
monitored by measuring the conversion of LA into the UV-
active 13-HpODE (λmax 234 nm). This assay was used to
determine IC50 of each compound. SARs for binding to 15-
LOX-1 were investigated starting from ethyl 6-chloro-1H-
indole-2-carboxylate (1). We aimed to introduce structural
modiﬁcations to replace the lipid chain at the 3-position and the
ethylcarboxylate at the 2-position. Key structural modiﬁcations
are shown in Figure 3 starting from previously identiﬁed
inhibitors 1 and Eleftheriadis-14d.30
The SAR of the previously identiﬁed inhibitor Eleftheriadis-
14d was explored with respect to aliphatic acyl substitutions at
the indole 3-position. To expand the SAR in novel directions,
the carboxyl ethyl ester at the indole 3-position was replaced by
an amide to gain metabolic stability. Both compounds 5a and 5b
(Scheme 1 and Table 1) provided IC50 values above 1 μM,
which is much higher compared to that of the previously
Scheme 4. Synthetic Route to Compounds 14−17a
aReagents and conditions: (i) LiOH, THF, H2O, 50 °C, 2 h; (j) EDCI, HOBt, Et3N, DCM, r.t., 4 h.
Figure 3. Systematic modiﬁcations of 15-LOX-1 inhibitor 1 as a core scaﬀold and the previously described inhibitor Eleftheriadis-14d30 to provide the
new inhibitors 5b, 9c, 15−17 and their IC50 values for 15-LOX-1 inhibition.
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reported series of inhibitors with the carboxyl ethyl ester.30
Apparently, replacement of the carbonyl at the indole 3-position
for an amide is unfavorable for 15-LOX-1 inhibition.
The SAR at the indole 3-position was further explored by
replacement of the carbonyl at the 3-position for a double bond
using Wittig chemistry. Using this chemistry, we aimed to
replace the aliphatic lipid chain in Eleftheriadis-14d for less
ﬂexible substituents. Thus, we investigated a series of E-alkenes
as shown in Table 2. Clear SARs were observed for this series of
compounds. Compound 9c (i472) proved to be themost potent
15-LOX-1 inhibitor with an IC50 value of 0.19 μM. Comparison
of inhibitor 9c (i472) to inhibitor 9f indicates that the ortho-
methoxy substitution on benzyl provides a 10-fold gain in
potency compared to that of a nonsubstituted benzyl.
Importantly, the IC50 values decrease if the methoxy group is
moved from the ortho to the meta or para position on benzyl 9d
and 9e. Extending the benzyl to an ethylphenyl group in
inhibitors 9g−j did not improve their potencies either. Taken
together, the 2-methoxybenzyl group in 9c (i472) provides the
most potent inhibitor in this series.
To further explore the SAR of previously identiﬁed inhibitor
Eleftheriadis-14d, variations were made at the indolyl 2-
position. Toward this aim, the ester group was replaced with
various amides to provide inhibitors 12a−g, as shown in Table 3.
The results indicate that amide substitution provides inhibitors
with potencies in the micromolar range. However, the SAR for
modiﬁcations with methyl, ethyl, n-propyl, n-butyl, n-pentyl, and
branched alkyl groups proved to be relatively ﬂat with potency
diﬀerences of no more than 2−3-fold. Remarkably, cyclopropyl
substitution in 12g turns out to be inactive (IC50 > 20 μM).
Taken together, the investigated series of amide-substituted
indoles did not provide improved potency and the most potent
inhibitor in this series is compound 12c with a propyl
substitution.
As a next step, we combined ethyl- or propyl-substituted
amides at the indole 2-position with substitutions at the 3-
position to provide inhibitors 14−17, as shown in Table 4.
Unfortunately, the combination of both modiﬁcations provided
inhibitors with low potency. Apparently, the more polar amide
bond is not well tolerated for enzyme inhibition and
combination of modiﬁcations at the 2- and 3-position caused a
greatly reduced potency. Inhibitor 13 also showed a complete
loss in potency against 15-LOX-1. Taken together, we
concluded that inhibitor 9c (i472) has the highest potency of
this series and that the IC50 value is in the same range as for the
previously identiﬁed inhibitor Eleftheriadis-14d.
2.3. Docking 15-LOX-1. To understand the observed SAR
key inhibitors were docked in the 15-LOX-1 active site. In this
study, docking was performed using Discovery Studio (Dassault
System̀es) version 2018. Moreover, the rabbit reticulocyte 15-
LOX-1 crystal structure (Protein Data Bank (PDB) ID: 1LOX)
was used for docking because of its high sequence similarity in
the active site.39 In this crystal structure, the ligand in the crystal
structure was removed and the center of the binding sphere was
set at the same position. Based on this position, CDocker, a
Table 1. IC50 Values for 15-LOX-1 Inhibition by Amide-
Substituted Indoles at the 3-Position (Analogues 5a and 5b)
Table 2. IC50 Values against 15-LOX-1 with Diﬀerent
Variations in R (Analogues 9a−j)
Table 3. IC50 Values against 15-LOX-1 with Diﬀerent
Variations in the Amide Tail (Analogues 12a−g)
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CHARMm-based method, was used and resulted in ten highest-
ranked poses for all selected inhibitors.
Based on the observed SAR, the most potent inhibitor 9c
(i472) was docked and compared to 9f (lacking the methoxy
group) and 16 (in which the ester is replaced for an amide). In
both cases, the potency decreased by at least 10-fold. The
docking model suggested several interactions between the active
site of 15-LOX-1 and 9c (i472), as shown in Figure 4A. Upon
comparison of the docking of 9c (i472) and 9f, the 2-methoxy
group on the benzyl functionality provides two hydrogen bonds
with GLN 548 and ILE 593, respectively (Figure 4A). This may
provide an explanation for the 10-fold potency diﬀerence
between 9c (i472) and 9f. In addition, because of the
hydrophobic character of 15-LOX-1, except from the edge of
Table 4. IC50 Values against 15-LOX-1 with Diﬀerent Variations in R
1 and R2 (Analogues 13−18)
Figure 4.Molecular modeling of selected compounds in the active site of 15-LOX-1 (PDB ID: 1LOX). The surface in the pocket is colored based on
the relative hydrophobicity: brown for hydrophobic and blue for hydrophilic areas. (A) Interactions of compound 9c (i472) with the active site of the
enzyme. (B) Preferred orientation of compound 9c (i472) in the active site of the enzyme. (C) Preferred orientation of compound 16 in the active site
of the enzyme that is inverted compared to 9c (i472).
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the active site, the majority of the pocket is hydrophobic, as
shown in brown in Figure 4B,C. The hydrophilic sites are shown
in blue. Docking of compound 16, in which an amide replaces
the carboxy ethyl ester at the indole 2-position, shows a
positionally inverted orientation compared to 9c (i472) and 9f
(Figures 4C and S1C). Apparently, the amide with an additional
hydrogen bond donor does not ﬁt at the same position as the
ester in 9c (i472). This change in orientation upon docking is
also in line with the observed drop in potency for 16 compared
to 9c (i472) and 9f.
2.4. Physicochemical Properties of Inhibitor 9c (i472).
The α,β-unsaturated amide functionality in 9c (i472) is, as a
Michael acceptor, reactive toward conjugate addition by
nucleophiles, such as thiols. To monitor this reactivity, the UV
spectrum of 9c (i472) was recorded upon incubation with 2-
mercaptoethanol at pH 7.4. No changes in the UV spectrum
were observed, which indicates that the chromophore, including
the α,β-unsaturated system, did not change (Figure S2), thus
indicating a reasonable stability of compound 9c (i472) toward
nucleophilic substitution. This stability might be attributed to
the conjugation of the α,β-unsaturated double bond with the
aromatic indole core.
Inhibitor 9c (i472) has a calculated Log P (ChemDraw
Professional version 12.0) of 4.7, which is more than 2 orders of
magnitude lower compared to the previously identiﬁed inhibitor
Eleftheriadis-14d (cLog P = 6.9), whereas both inhibitors have
molecular weights around 400 g/mol. Considering the
physicochemical properties, the newly identiﬁed inhibitor 9c
(i472) has fewer rotatable bonds and a cLog P that is more
favorable for cellular permeability compared to the previously
identiﬁed inhibitor Eleftheridis-14d.
2.5. LOX Inhibitory Potency of 9c (i472) in Cells by
Activity-Based Labeling. As a next step in the character-
ization of inhibitor 9c (i472), the inhibition of cellular LOX
activity was investigated. Toward this aim, we employed a
method for activity-based labeling of LOX activity in cell-based
systems that we developed recently.34 In this method, a covalent
inhibitor of lipoxygenase activity is equipped with a terminal
alkene for bioorthogonal labeling with biotin using the oxidative
Heck reaction.40 Here, we employed this method to estimate the
inhibition of cellular lipoxygenase activity by inhibitor 9c (i472)
in RAW 264.7 macrophages. Inhibitor-treated and nontreated
cell lysates were exposed to covalent inhibitor N144 (Figure 2)
for 2 min, and subsequently, the samples were subjected to the
oxidative Heck reaction to link a biotinylated phenylboronic
acid for detection. In parallel to the labeling, the same samples
were subjected to staining for β-actin as a loading control and
antibody-based detection of the amount of 15-LOX-1.
Representative blots are shown in Figure 5. We observed a
decreased intensity for the band for activity-based lipoxygenase
labeling as detected by streptavidin−horseradish peroxidase
(HRP). For comparison, the bands normalized with the β-actin
antibody and the 15-LOX antibody were included as well, which
show comparable intensities. Quantiﬁcations of the bands from
three independent experiments are shown in Figure 6. From
these results, we conclude that 15-LOX-1 inhibitor 9c (i472) is
able to inhibit the activity of cellular lipoxygenases.
2.6. Protection of RAW 264.7 Macrophages from LPS-
Induced Cytotoxicity. After identifying compound 9c (i472)
as a potent inhibitor for recombinant expressed 15-LOX-1 and
cellular LOX activity, we moved on to investigate the potency of
this compound in cell-based studies. As the insight into the
mechanism, we presume that 15-LOX-1 inhibitors inhibit the
formation of lipid peroxides in cells, thereby preventing
ferroptotic cell death. Additionally, we expect this mechanism
to have crosstalk with the NF-κB pathway. Activation of this
pathway can also lead to cell death. To test this hypothesis, we
employed a model in which we stimulated RAW 264.7
macrophages with LPS to cause cell death, as reported
previously.3 This study reported an LD50 of 89.5 μg/mL for
LPS-induced cell death in macrophages. In our experiments,
40% inhibition of cell viability was obtained at 100 μg/mL
(Figure S3). Subsequently, as shown in Figure 7, we employed
an LPS concentration of 100 μg/mL and investigated the
protection from cell death by treatment with lipoxygenase
inhibitors. The 5-LOX inhibitor Zileuton and the previously
identiﬁed 15-LOX-1 inhibitor Eleftheriadis-14d comparably
improved the viability of LPS-treated RAW 264.7 macrophages.
In addition, inhibitor 9c (i472) showed stronger, dose-
dependent eﬀects with a 20% viability increase at 5 μM. Thus,
these data demonstrated that inhibiting 15-LOX-1 by
compound 9c (i472) can protect RAW 264.7 macrophages
from LPS-induced cell death.
2.7. NF-κB Activity Determination. To gain further
insight into the mechanism of protection for LPS-induced cell
death, we investigated the eﬀect of inhibitor 9c (i472) onNF-κB
activity using an NF-κB reporter assay on RAW-Blue macro-
phages (modiﬁed RAW 264.7 macrophages). These RAW-Blue
Figure 5.Detection of the eﬀect of inhibitor 9c (i472) on the activity of
15-LOX-1 by an activity-based probe. Labeling was performed on cell
lysis of RAW 264.7 cells. Positive control (with probe and without
inhibitor), negative control (without probe or inhibitor), and
incubation of 9c (i472) were performed with the 15-LOX antibody,
β-actin antibody, and streptavidin−HRP (n = 3).
Figure 6. Quantiﬁcation of Western blots for detection and analysis of
activity-based labeling: The values are measured by integrating the gray
values by ImageJ 1.44. The integrated gray values of streptavidin−HRP
and 15-LOX are normalized to β-actin, respectively. All of the values
were expressed as mean ± standard error of the mean (SEM). The
results were normalized by three independent experiments (n = 3). *p <
0.05, **p < 0.005, and ***p < 0.001 compared to control by the two-
tailed test.
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macrophages can stably express a secreted embryonic alkaline
phosphatase (SEAP) gene that is inducible by NF-κB and AP-1
transcription factors. Previous evidence demonstrated that the
product of 15-LOX-1 and 13-HpODE can increase NF-κB
activation but has no eﬀect on AP-1.8 The cells were stimulated
with LPS, interferon γ (IFNγ), and inhibitor 9c (i472).41 This
provided signiﬁcant but not complete inhibition of NF-κB
transcriptional activation upon LPS/INFγ stimulation (Figure
8). These results are in line with the anticipated crosstalk
between 15-LOX-1 inhibition and NF-κB signaling.
2.8. Gene Expression. Subsequently, we turned our
attention to the inﬂuence of 15-LOX-1 inhibition by 9c
(i472) on the gene expression of NF-κB-related gene iNOS
(Figure 9). As a model, we used RAW 264.7 macrophages that
were activated by LPS and IFNγ (10 ng/mL of each).42 The
gene expression of iNOS was downregulated by approximately
50% at 5 μM. This ﬁnding is in line with but more pronounced
than the observed decrease in NF-κB transcriptional activity
(Figure 8).
2.9. Quantiﬁcation of Nitric Oxide (NO) Production.
Gene transcription of iNOS is connected to NO production,
which plays an important role in the regulation of immune
response and apoptosis. In our study, we compared the
inhibitory eﬀects of 9c (i472) on the ratio of total nitrate to
nitrite in RAW 264.7 macrophages (Figure 10). We
demonstrated that 9c (i472) as a 15-LOX-1 inhibitor provided
dose-dependent inhibition of NO production, which is
consistent with the results of reduced activity of NF-κB and
the gene expression of iNOS. The observations that 15-LOX
inhibition inhibits NF-κB reporter gene activity, iNOS
expression, and NO levels are in line with the idea that there
is crosstalk between 15-LOX-1 activity and cell death via activity
of the NF-κB pathway and NO production.
2.10. Lipid Peroxidation.Oxidative stress can cause a series
of toxic eﬀects through the production of lipid peroxides that
play a role in cell death.43 The eﬀect of lipoxygenase inhibitor 9c
(i472) on lipid peroxidation in RAW 264.7 cells was
investigated using the ﬂuorescent dye dipyrrometheneboron
diﬂuoride (BODIPY) 581/591 C11 and ﬂuorescence-activated
cell sorting (FACS).44 As shown in Figure 11, 15-LOX inhibitor
PD-146176 and 9c (i472) revealed comparable eﬀects that
both of them signiﬁcantly attenuated the boost of lipid peroxides
Figure 7. Inhibitor 9c (i472) protects RAW 264.7 macrophages from
LPS-induced cytotoxicity. RAW 264.7 macrophages were treated with
lipopolysaccharides (LPSs) (100 μg/mL) and 9c (i472) together for 24
h. Then, the cell viability was determined by a 3-(4,5-dimethylthiazol-2-
yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium
(MTS) assay (n = 3−13). All of the values were expressed as mean ±
SEM. *p < 0.05, **p < 0.005, and ***p < 0.001 compared to positive
control by the two-tailed test that is only with the treatment of LPS (100
μg/mL) for 48 h.
Figure 8. Inhibitor 9c (i472) reduces NF-κB activity. RAW-Blue
macrophages were pretreated with inhibitor 9c (i472) at 0.2, 1, and 5
μM for 20 h, after which inﬂammatory lipopolysaccharide (LPS) and
interferon γ (IFNγ) stimuli (10 ng/mL of each) were given for another
4 h in continued presence of inhibitor 9c. All of the values were
expressed as mean ± SEM (n = 8−16). *p < 0.05, **p < 0.005, and
***p < 0.001 compared to positive control that is treated with LPS and
IFNγ by the two-tailed test.
Figure 9. Eﬀect of inhibition of 15-LOX-1 by 9c (i472) on iNOS in
RAW 264.7 cells: Lipopolysaccharide (LPS)/interferon γ (IFNγ) (10
ng/mL of each)-stimulated cells were normalized to the positive
control. All experimental groups were treated with compound 9c
(i472) at 0.2, 1, and 5 μM for 20 h and stimulated with LPS/IFNγ for
another 4 h (n = 3−4). All of the values were expressed as mean± SEM.
*p < 0.05, **p < 0.005, and ***p < 0.001 compared to the LPS/IFNγ-
treated positive control group by the two-tailed test.
Figure 10. Dose-dependent eﬀect of 9c (i472) on the expression of
total nitrate/nitrite in RAW 264.7 cells: Lipopolysaccharide (LPS)/
interferon γ (IFNγ) (10 ng/mL of each)-stimulated cells were
corrected to 100% as positive control. All experimental groups were
treated with compound 9c (i472) at 0.2, 1, and 5 μM for 20 h and
stimulated with LPS/IFNγ for another 4 h (n = 3). All of the values were
expressed as mean ± SEM. *p < 0.05, **p < 0.005, and ***p < 0.001
compared to the LPS/IFNγ-treated control group by the two-tailed
test.
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at 5 μM after the treatment of LPS/IFNγ (10 ng/mL of each).
This result could be attributed to loss of 15-LOX products, such
as 13-HpODE. Furthermore, compared to the 5-LOX inhibitor,
Zileuton, both 15-LOX-1 inhibitors showed a more pro-
nounced eﬀect on lipid peroxidation, ﬁtting the result of LPS-
induced cell death assay that the 15-LOX-1 inhibitor has a better
rescue eﬀect. Although 15-LOX-1 is not the only pathway that
can trigger lipid peroxide formation, these results indicate that
inhibition of 15-LOX-1 has a strong inﬂuence on lipid
peroxidation in this model system.
3. CONCLUSIONS
In this study, compound 9c (i472) was developed as a potent
15-LOX-1 inhibitor with a novel substituent pattern (IC50 = 0.19
μM) and its SARs were explored. Using activity-based labeling,
we demonstrated that inhibitor 9c (i472) was able to inhibit
cellular lipoxygenases. Further characterization of this com-
pound demonstrated that it was able to protect RAW 264.7
macrophages from LPS-induced cell death. We explored the
inﬂuence of inhibitor 9c (i472) on diﬀerent pathways of cell
death. We investigated NF-κB activation, iNOS expression, and
NO formation as a line of events that can trigger cell death.
Treatment with inhibitor 9c (i472) enabled downregulation of
the NF-κB transcriptional activity in a reporter gene assay.
Furthermore, we demonstrated that iNOS gene expression and
the levels of NO in RAW 264.7 macrophages decreased
signiﬁcantly upon 9c (i472) treatment. As a direct eﬀect of
inhibiting lipoxygenase activity, we investigated inhibition of
cellular lipid peroxidation upon 9c (i472) treatment, for which
we observed a clear reduction back to baseline levels. Having
explored both mechanisms, we can conclude that inhibitor 9c
(i472) inﬂuences both NO production and lipid peroxidation,
potentially via a crosstalk mechanism. Thus, we conclude that
we provide a novel 15-LOX-1 inhibitor 9c (i472) with cellular
activity that inhibits the formation of oxidative mediators, such
as NO and lipid peroxides, that are connected to diﬀerent
mechanisms for cell death.
4. EXPERIMENTAL SECTION
4.1. General. All reagents, solvents, and catalysts were purchased
from commercial sources (Acros Organics, Sigma-Aldrich, and abcr
GmbH, Netherlands) and used without puriﬁcation. Reactions that
required exclusion of oxygen or water were performed in oven-dried
ﬂasks under nitrogen atmosphere. Reactions were monitored by thin-
layer chromatography (TLC) on TLC precoated (250 μm) silica gel 60
F254 aluminum foil (EMD Chemicals Inc.). Visualization was achieved
using UV light. Alternatively, non-UV-active compounds were detected
after staining with potassium permanganate. Flash column chromatog-
raphy was performed on silica gel (32−63 μm, 60 Å pore size). 1H
NMR (500 MHz) and 13C NMR (126 MHz) spectra were recorded
with a Bruker Avance four-channel NMR spectrometer with a TXI
probe. Chemical shifts (δ) are reported in ppm. Abbreviations are as
follows: singlet (s), doublet (d), triplet (t), quartet (q), and multiplet
(m). Fourier transform mass spectrometry and electrospray ionization
were performed on an Applied Biosystems/SCIEX API 3000-triple
quadrupole mass spectrometer. High-performance liquid chromatog-
raphy (HPLC) analysis was performed for conﬁrming purity with a
Shimadzu LC-10AT HPLC, with a Shimadzu SP-M10A ELSD
detector, and with a Shimadzu SPD-M10A photodiode array detector.
Analytical HPLCwas performed using a Kinetex C18 column (150 mm
× 4.6 mm, 5 μm) with 5−95% MeCN gradient in H2O as a mobile
phase, conﬁrming purity≥95%. Retention time (RT) of HPLCwas also
reported.
4.2. Synthesis and Characterization. 4.2.1. Ethyl 6-Chloro-3-
formyl-1H-indole-2-carboxylate (2). To a solution of POCl3 (0.30
mL, 3.2 mmol, 1.2 equiv) in DMF (6.0 mL) stirred at 0 °C for 0.5 h, 1
(0.60 g, 2.7 mmol) was added, and the reaction mixture was heated to
50 °C for 46 h. After completion, the reaction mixture was slowly
poured into a mixture of crushed ice and H2O (300 mL). The product
was obtained by ﬁltration of the resulting suspension. The residue was
washed with acetonitrile and dried at r.t., giving the title intermediate 2
as a yellow solid in a yield of 83% (0.55 g, 2.2 mmol). The NMR spectra
were the same as reported previously.36
4.2.2. 6-Chloro-2-(ethoxycarbonyl)-1H-indole-3-carboxylic Acid
(3). To a solution of 2 (0.10 g, 0.39 mmol) and NaClO2 (71 mg, 0.78
mmol) was added 5.0 mL of t-BuOH at 50 °C for 4 h. After reaction
completion, the mixture was concentrated and H2O (50 mL) was
added, followed by extraction with EtOAc (3 × 15 mL). The organic
phases were collected and evaporated, giving a white crude product
without further puriﬁcation in 82% yield.
4.2.3. General Synthetic Procedure 1: Amide Bond Formation.
The respective carboxylic acid (1.0 equiv) was added to a mixture of
HOBt (0.40 equiv), EDCI (2.0 equiv), and Et3N (1.0 equiv) in CH2Cl2
(20 mL) at room temperature for 30 min. After stirring, the respective
amine (1.5 equiv) was added to this reaction mixture, which was
subsequently stirred at room temperature for 4 h. Then, the reaction
mixture was washed with 1.0 M aqueous HCl (5.0 mL), sat. aqueous
NaHCO3 (5.0 mL), and brine (5.0 mL); dried over MgSO4; ﬁltered;
and concentrated under reduced pressure. The crude product was
puriﬁed by column chromatography and eluted with 20% ethyl acetate
in DCM as a solvent to obtain a white solid product with a general yield
from 70 to 80%.
4.2.4. Ethyl 6-Chloro-3-(propylcarbamoyl)-1H-indole-2-carboxy-
late (5a). The product was obtained using general procedure 1 starting
from carboxylate 3 and propylamine. The product was obtained as a
yellow solid in 86% yield. 1H NMR (500 MHz, dimethyl sulfoxide
(DMSO)-d6) δ 12.96 (s, 1H), 8.92 (t, J = 5.5 Hz, 1H), 8.57 (d, J = 2.5
Hz, 1H), 7.87 (d, J = 8.5Hz, 1H), 7.35 (dd, J = 8.5, 2.5 Hz, 1H), 4.31 (q,
J = 7.0Hz, 2H), 3.26−3.23 (m, 2H), 1.59−1.52 (m, 2H), 1.32 (t, J = 7.0
Hz, 3H), 0.91 (t, J = 7.0 Hz, 3H). 13C NMR (126 MHz, DMSO-d6) δ
167.37, 160.16, 154.97, 139.38, 136.90, 130.43, 130.37, 124.08, 120.02,
119.90, 63.31, 41.49, 22.49, 14.26, 11.88. High-resolution mass
spectrometry (HRMS), calcd for C15H18ClO2N3 [M + H]
+:
309.1000, found 309.1002. HPLC: purity 96%, retention time 17.7 min.
4.2.5. Ethyl (R)-6-Chloro-3-((2,6-dimethylheptyl)carbamoyl)-1H-
indole-2-carboxylate (5b). The product was obtained using general
procedure 1 starting from carboxylate 3. The product was obtained as a
yellow solid in 82% yield. 1HNMR (500MHz, CDCl3) δ 10.75 (s, 1H),
9.40 (s, 1H), 8.43 (d, J = 8.5 Hz, 1H), 7.50 (d, J = 2.0 Hz, 1H), 7.36 (dd,
J = 8.5, 2.0 Hz, 1H), 5.75 (s, 1H), 4.56 (q, J = 7.0 Hz, 2H), 3.25−3.06
(m, 1H), 1.54 (m, 1H), 1.51 (t, J = 5.0 Hz, 3H), 1.36−1.15 (m, 8H),
0.96 (d, J = 6.0 Hz, 3H), 0.93 (d, J = 6.0 Hz, 3H). 13C NMR (126MHz,
DMSO-d6) δ 166.71, 160.13, 154.91, 139.28, 136.81, 131.58, 130.40,
124.03, 120.33, 119.92, 63.29, 45.55, 38.70, 36.64, 36.34, 27.81, 24.04,
Figure 11. Analysis of lipid peroxidation using BODIPY 581/591 C11
staining and FACS analysis. Cells were treated with lipopolysaccharide
(LPS)/interferon γ (IFNγ) (10 ng/mL of each) and PD-146176 (5
μM), Zileuton (5 μM), or 9c (i472) (5 μM). Results are represented as
mean ± SEM (n = 3). *p < 0.05, **p < 0.005, and ***p < 0.001
compared to the LPS/IFNγ-treated control group by the two-tailed
test.
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22.87, 20.86, 14.26, 14.18. HRMS, calcd for C21H30ClN2O3 [M + H]
+:
393.1939, found 393.1938. HPLC: purity 99%, retention time 14.3min.
4.2.6. Ethyl (E)-3-(3-(tert-Butoxy)-3-oxoprop-1-en-1-yl)-6-chloro-
1H-indole-2-carboxylate (6). 2 (0.10 g, 0.39 mmol), (tert-
butoxycarbonylmethylene)triphenylphosphorane (0.17 g, 0.50
mmol), and EtOH (10 mL) were mixed under an atmosphere of
nitrogen in an oven-dried ﬂask. The mixture was heated at reﬂux for 2 h.
Then, the solvent was evaporated under reduced pressure. The product
was puriﬁed by column chromatography and eluted with 20% ethyl
acetate in petroleum as a solvent, and a yellow solid product was
obtained in 84% yield. The NMR spectra were the same as reported
previously.45
4.2.7. (E)-3-(6-Chloro-2-(ethoxycarbonyl)-1H-indol-3-yl)acrylic
Acid (7). 6 (0.50 g, 1.7 mmol) was dissolved in DCM (1 mL). Then,
triﬂuoroacetic acid (1.0 mL, 2.0 mmol) was added and the mixture was
stirred at 0 °C for 2 h. After evaporation of the solvent, the crude
product did not need further puriﬁcation. The NMR spectra were the
same as reported previously.45
4.2.8. Ethyl (E)-6-Chloro-3-(3-((2,4-dichlorobenzyl)amino)-3-ox-
oprop-1-en-1-yl)-1H-indole-2-carboxylate (9a). The product was
obtained using general procedure 1 starting from 7. The product was
obtained as a white solid in 89% yield. 1H NMR (500MHz, DMSO-d6)
δ 12.31 (s, 1H), 8.63 (t, J = 6.0 Hz, 1H), 8.34 (d, J = 16.0 Hz, 1H), 8.06
(d, J = 8.5 Hz, 1H), 7.65 (d, J = 2.0 Hz, 1H), 7.55 (d, J = 2.0 Hz, 1H),
7.48−7.43 (m, 2H), 7.28 (dd, J = 8.5, 2.0 Hz, 1H), 7.24 (d, J = 16.0 Hz,
1H), 4.48 (d, J = 6.0 Hz, 2H), 4.41 (q, J = 7.0 Hz, 2H). 1.39 (t, J = 7.0
Hz, 3H). 13C NMR (126 MHz, DMSO-d6) δ 166.16, 161.20, 137.57,
136.10, 133.64, 132.81, 132.02, 131.12, 130.47, 129.09, 127.88, 127.66,
123.97, 123.71, 122.58, 122.37, 117.17, 113.10, 105.90, 61.59, 14.69.
HRMS, calcd for C21H18Cl3N2O3 [M + H]
+: 451.0378, found
451.0377. HPLC: purity 95%, retention time 19.2 min.
4.2.9. Ethyl (E)-6-Chloro-3-(3-((2-chlorobenzyl)amino)-3-oxo-
prop-1-en-1-yl)-1H-indole-2-carboxylate (9b). The product was
obtained using general procedure 1 starting from 7. The product was
obtained as a white solid in 89% yield. 1H NMR (500MHz, DMSO-d6)
δ 12.32 (s, 1H), 8.59 (t, J = 5.5 Hz, 1H), 8.34 (d, J = 16.0 Hz, 1H), 8.07
(d, J = 6.0 Hz, 1H), 8.55 (d, J = 2.0 Hz, 1H), 7.48 (dd, J = 7.0, 2.0 Hz,
1H), 7.43 (dd, J = 7.0, 2.0 Hz, 1H), 7.35 (m, 2H), 7.28 (dd, J = 7.0, 2.0
Hz, 1H), 7.03 (d, J = 16 Hz, 1H), 4.50 (d, J = 6.0 Hz, 2H), 4.42 (q, J =
6.0 Hz, 2H), 1.39 (t, J = 6.0 Hz, 3H). 13C NMR (126 MHz, DMSO-d6)
δ 171.36, 166.33, 141.59, 140.42, 134.65, 134.42, 133.89, 133.21,
131.51, 130.11, 129.20, 127.64, 126.67, 125.90, 122.91, 122.09, 117.00,
99.98, 65.72, 34.31, 19.24. HRMS, calcd for C21H19O3N2Cl2 [M +H]
+:
417.0767, found 417.0767. HPLC: purity 96%, retention time 19.2min.
4.2.10. Ethyl (E)-6-Chloro-3-(3-((2-methoxybenzyl)amino)-3-ox-
oprop-1-en-1-yl)-1H-indole-2-carboxylate (9c). The product was
obtained using general procedure 1 starting from 7. The product was
obtained as a white solid in 79% yield. 1H NMR (500MHz, DMSO-d6)
δ 12.28 (s, 1H), 8.39 (t, J = 5.5 Hz, 1H), 8.31 (d, J = 16.0, Hz, 1H), 8.08
(d, J = 9.0, Hz, 1H), 7.54 (dd, J = 7.0, 2.0 Hz, 1H), 7.42−7.29 (m, 3H),
7.03 (s, 1H), 7.01 (d, J =7.0 Hz, 1H), 6.94 (td, J = 7.0, 2.0 Hz, 1H),
4.43−4.38 (m, 4H), 3.83 (s, 3H), 1.39 (t, J = 7.0 Hz, 3H). 13C NMR
(126 MHz, DMSO-d6) δ 165.97, 161.25, 157.28, 141.43, 137.57,
131.43, 130.44, 128.78, 127.53, 125.63, 124.96, 124.11, 123.96, 122.30,
120.66, 117.37, 113.09, 111.04, 61.57, 55.78, 38.81, 14.73. HRMS,
calcd for C22H22ClN2O4 [M + H]
+: 413.1263, found 413.1261. HPLC:
purity 96%, retention time 18.9 min.
4.2.11. Ethyl (E)-6-Chloro-3-(3-((3-methoxybenzyl)amino)-3-ox-
oprop-1-en-1-yl)-1H-indole-2-carboxylate (9d). The product was
obtained using general procedure 1 starting from 7. The product was
obtained as a white solid in 91% yield. 1H NMR (500MHz, DMSO-d6)
δ 12.30 (s, 1H), 8.55 (t, J = 6.0 Hz, 1H), 8.34 (d, J = 16.0 Hz, 1H), 8.05
(d, J = 8.5 Hz, 1H), 7.55 (d, J =2.0 Hz, 1H), 7.29−7.25 (m, 2H), 6.94
(d, J = 16.0 Hz, 1H), 6.91 (m, 2H), 6.85 (dd, J = 7.0, 2.0 Hz, 1H), 4.44−
4.40 (m, 4H), 3.74 (s, 3H), 1.39 (t, J = 7.0 Hz, 3H). 13C NMR (126
MHz, DMSO-d6) δ 165.92, 161.24, 159.82, 141.43, 137.57, 131.69,
130.45, 129.68, 127.53, 125.63, 124.96, 123.97, 123.05, 122.34, 120.13,
117.30, 113.66, 112.71, 61.58, 55.54, 42.84, 14.75. HRMS, calcd for
C22H22ClN2O4 [M + H]
+: 413.1263, found 413.1262. HPLC: purity
96%, retention time 14.4 min.
4.2.12. Ethyl (E)-6-Chloro-3-(3-((4-methoxybenzyl)amino)-3-ox-
oprop-1-en-1-yl)-1H-indole-2-carboxylate (9e). The product was
obtained using general procedure 1 starting from 7. The product was
obtained as a white solid in 84% yield. 1H NMR (500MHz, DMSO-d6)
δ 12.29 (s, 1H), 8.49 (t, J = 6.0 Hz, 1H), 8.34 (d, J = 16.0 Hz, 1H), 8.04
(d, J = 6.0 Hz, 1H), 7.54 (d, J = 2.0 Hz, 1H), 7.26 (m, 3H), 6.97−6.91
(m, 3H), 4.43 (q, J = 6.0 Hz, 2H), 4.35 (d, J = 6.0Hz, 2H), 3.74 (s, 3H),
1.39 (t, J = 6.0 Hz, 3H). 13C NMR (126 MHz, DMSO-d6) δ 165.77,
161.24, 158.78, 137.56, 131.76, 131.52, 130.43 (2×), 129.35, 127.48,
123.95, 123.72, 123.22, 122.32, 117.33, 114.27, 114.21, 113.11, 61.58,
55.52, 42.35, 14.67. HRMS, calcd for C22H22ClN2O4 [M + H]
+:
413.1263, found 413.1262. HPLC: purity 95%, retention time 14.4 min.
4.2.13. Ethyl (E)-3-(3-(Benzylamino)-3-oxoprop-1-en-1-yl)-6-
chloro-1H-indole-2-carboxylate (9f). The product was obtained
using general procedure 1 starting from 7. The product was obtained
as a white solid in 88% yield. 1H NMR (500 MHz, DMSO-d6) δ 12.30
(s, 1H), 8.57 (t, J = 6.0 Hz, 1H), 8.33 (d, J = 16.0 Hz, 1H), 8.05 (d, J =
6.0 Hz, 1H), 7.55 (d, J = 2.0 Hz, 1H), 7.38−7.25 (m, 6H), 6.67 (d, J =
16.0 Hz, 1H), 4.44−4.40 (m, 4H), 1.38 (t, J = 6.0 Hz, 3H). 13C NMR
(126 MHz, DMSO-d6) δ 165.91, 161.24, 139.86, 137.56, 131.68,
131.62, 130.44, 128.86 (2×), 127.98, 127.52, 127.38, 123.96, 123.77,
123.08, 122.34, 117.30, 113.02, 61.59, 42.88, 14.76. HRMS, calcd for
C21H20ClN2O3 [M + H]
+: 383.1157, found 383.1158. HPLC: purity
98%, retention time 7.1 min.
4.2.14. Ethyl (E)-6-Chloro-3-(3-oxo-3-(phenethylamino)prop-1-
en-1-yl)-1H-indole-2-carboxylate (9g). The product was obtained
using general procedure 1 starting from 7. The product was obtained as
a white solid in 76% yield. 1H NMR (500 MHz, DMSO-d6) δ 12.28 (s,
1H), 8.29 (d, J = 16.0 Hz, 1H), 8.19 (t, J = 6.0 Hz, 1H), 8.02 (d, J = 7.5
Hz, 1H), 7.54 (d, J = 2.0 Hz, 1H), 7.34−7.21 (m, 6H), 6.90 (d, J = 16.0
Hz, 1H), 4.42 (q, J = 6.0 Hz, 2H), 4.45 (q, J = 6.0 Hz, 2H), 2.81 (t, J =
6.0 Hz, 2H), 1.38 (t, J = 6.0 Hz, 3H). 13C NMR (126 MHz, DMSO-d6)
δ 165.90, 161.24, 144.40, 139.98, 137.58, 137.13, 131.26, 130.41 (2×),
129.09, 128.82, 126.57, 123.97, 123.70, 123.26, 122.28, 117.34, 113.06,
61.55, 39.77, 35.74, 14.71. HRMS, calcd for C22H22ClN2O3 [M + H]
+:
397.1313, found 397.1311. HPLC: purity 96%, retention time 14.5 min.
4.2.15. Ethyl (E)-6-Chloro-3-(3-((2-chlorophenethyl)amino)-3-ox-
oprop-1-en-1-yl)-1H-indole-2-carboxylate (9h). The product was
obtained using general procedure 1 starting from 7. The product was
obtained as a white solid in 90% yield. 1H NMR (500MHz, DMSO-d6)
δ 12.28 (s, 1H), 8.28 (d, J = 16.0 Hz, 1H), 8.24 (t, J = 6.0 Hz, 1H), 8.02
(d, J = 9.0 Hz, 1H), 7.55 (d, J = 2.0 Hz, 1H), 7.46 (dd, J = 8.0, 2.0 Hz,
1H), 7.38 (dd, J = 8.0, 2.0Hz, 1H), 7.33−7.26 (m, 3H), 6.87 (d, J = 16.0
Hz, 1H), 4.42 (q, J = 7.0 Hz, 2H), 3.45 (q, J = 7.0 Hz, 2H), 2.95 (t, J =
7.0 Hz, 2H), 1.40 (t, J = 7.0 Hz, 3H). 13C NMR (126 MHz, DMSO-d6)
δ 166.01, 161.53, 137.21, 136.78, 133.50, 131.21, 129.66, 129.44,
128.67, 128.58, 127.78, 127.68, 125.82, 125.02, 123.80, 120.88, 118.46,
112.26, 61.13, 38.63, 33.14, 14.71. HRMS, calcd for C22H21O3N2Cl2
[M + H]+: 431.0924, found 431.0924. HPLC: purity 95%, retention
time 14.2 min.
4.2.16. Ethyl (E)-6-Chloro-3-(3-((2,4-dichlorophenethyl)amino)-3-
oxoprop-1-en-1-yl)-1H-indole-2-carboxylate (9i). The product was
obtained using general procedure 1 starting from 7. The product was
obtained as a white solid in 89% yield. 1H NMR (500MHz, DMSO-d6)
δ 12.29 (s, 1H), 8.28 (d, J = 16.0 Hz, 1H), 8.22 (t, J = 6.0 Hz, 1H), 8.01
(d, J = 9.0 Hz, 1H), 7.62 (d, J = 2.0 Hz, 1H), 7.55 (d, J = 2.0 Hz, 1H),
7.40 (m, 2H), 7.28 (m, 1H), 6.85 (d, J = 16.0 Hz, 1H), 4.42 (q, J = 7.0
Hz, 2H), 3.48 (q, J = 7.0 Hz, 2H), 2.91 (t, J = 7.0 Hz, 2H), 1.36 (t, J =
7.0 Hz, 3H). 13C NMR (126 MHz, DMSO-d6) δ 165.97, 161.22,
137.55, 136.49, 134.57, 132.79, 132.21, 131.38, 130.44, 129.12, 127.86,
127.49, 123.97, 123.65, 123.13, 122.32, 117.29, 113.07, 61.56, 38.69,
32.96, 14.70. HRMS, calcd for C22H20O3N2Cl3 [M + H]
+: 465.0534,
found 465.0534. HPLC: purity 95%, retention time 18.2 min.
4.2.17. Ethyl (E)-6-Chloro-3-(3-((2-methoxyphenethyl)amino)-3-
oxoprop-1-en-1-yl)-1H-indole-2-carboxylate (9j). The product was
obtained using general procedure 1 starting from 7. The product was
obtained as a white solid in 81% yield. 1H NMR (500MHz, DMSO-d6)
δ 12.27 (s, 1H), 8.27 (d, J = 16.0 Hz, 1H), 8.17 (t, J = 5.5 Hz, 1H), 8.02
(d, J = 8.5 Hz, 1H), 7.54 (d, J = 2.0 Hz, 1H), 7.27 (dd, J = 8.0, 2.0 Hz,
1H), 7.22 (m, 1H), 7.18 (dd, J = 7.0, 2.0 Hz, 1H), 6.99 (d, J = 16.0 Hz,
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1H), 6.89 (m, 2H), 4.42 (q, J = 7.0 Hz, 2H), 3.81 (s, 3H), 3.32 (q, J =
7.0 Hz, 2H), 2.78 (t, J = 7.0 Hz, 2H), 1.39 (t, J = 7.0 Hz, 3H). 13C NMR
(126 MHz, DMSO-d6) δ 165.84, 161.25, 157.71, 137.56, 131.17,
130.43, 128.09, 127.61, 127.41, 123.96, 123.75, 123.68, 123.41, 122.31,
117.38, 113.11, 113.00, 111.12, 61.56, 55.80, 55.71, 30.50, 14.75.
HRMS, calcd for C23H24O4N2Cl [M +H]
+: 427.1419, found 427.1418.
HPLC: purity 96%, retention time 17.2 min.
4.2.18. 6-Chloro-N-methyl-1H-indole-2-carboxamide (12a). The
product was obtained using general procedure 1 starting from 10. The
product was obtained as a light brown solid in 92% yield. 1HNMR (500
MHz, DMSO-d6) δ 11.72 (s, 1H), 8.53 (d, J = 5.0 Hz, 1H), 7.65 (d, J =
8.5 Hz, 1H), 7.43 (d, J = 2.0 Hz, 1H), 7.09 (d, J = 2.0 Hz, 1H), 7.05 (dd,
J = 8.5, 2.0 Hz, 1H), 2.82 (d, J = 4.5 Hz, 3H). 13C NMR (126 MHz,
CDCl3) δ 172.08, 162.03, 143.15, 135.19, 125.34, 125.14, 122.83,
113.47, 99.98, 35.69. HRMS, calcd for C10H10ClN2O [M + H]
+:
209.0476, found 209.0475. HPLC: purity 95%, retention time 18.5min.
4.2.19. 6-Chloro-N-ethyl-1H-indole-2-carboxamide (12b). The
product was obtained using general procedure 1 starting from 10.
The product was obtained as a light brown solid in 94% yield. 1H NMR
(500MHz, DMSO-d6) δ 11.70 (s, 1H), 8.65 (t, J = 6.0Hz, 1H), 7.69 (d,
J = 8.5 Hz, 1H), 7.43 (d, J = 2.0 Hz, 1H), 7.12 (d, J = 2.0 Hz, 1H), 7.06
(dd, J = 8.5, 2.0 Hz, 1H), 3.31 (m, 2H), 1.15 (t, J = 7.5 Hz, 3H). 13C
NMR (126MHz, DMSO-d6) δ 160.95, 137.05, 133.44, 128.15, 126.35,
123.55, 120.62, 112.17, 102.68, 34.13, 15.38. HRMS, calcd for
C11H12ON2Cl [M + H]
+: 223.0633, found 223.0633. HPLC: purity
98%, retention time 10.8 min.
4.2.20. 6-Chloro-N-propyl-1H-indole-2-carboxamide (12c). The
product was obtained using general procedure 1 starting from 10. The
product was obtained as a light brown solid in 91% yield. 1HNMR (500
MHz, DMSO-d6) δ 11.70 (s, 1H), 8.56 (t, J = 5.5 Hz, 1H), 7.64 (d, J =
8.5 Hz, 1H), 7.45 (d, J = 2.0 Hz, 1H), 7.15 (d, J = 2.0 Hz, 1H), 7.05 (dd,
J = 8.5, 2.0 Hz, 1H), 3.25 (q, J = 7.0 Hz, 2H), 1.55 (q, J = 7.5 Hz, 2H),
0.91 (d, J = 2.0 Hz, 1H). 13C NMR (126 MHz, DMSO-d6) δ 161.14,
137.07, 133.42, 128.18, 126.36, 123.54, 120.57, 112.18, 102.75, 41.06,
22.97, 11.94. HRMS, calcd for C12H14ON2Cl [M + H]
+: 237.0789,
found 237.0789. HPLC: purity 95%, retention time 14.5 min.
4.2.21. N-Butyl-6-chloro-1H-indole-2-carboxamide (12d). The
product was obtained using general procedure 1 starting from 10.
The product was obtained as a light brown solid in 90% yield. 1H NMR
(500MHz, DMSO-d6) δ 11.96 (s, 1H), 7.45 (t, J = 6.0Hz, 1H), 6.64 (d,
J = 8.5 Hz, 1H), 7.43 (d, J = 2.0 Hz, 1H), 7.14 (d, J = 2.0 Hz, 1H), 7.20
(dd, J = 8.5, 2.0 Hz, 1H), 3.32 (q, J = 7.5 Hz, 2H), 1.57−1.53 (m, 2H),
1.39−1.34 (m, 2H), 0.90 (t, J = 7.5 Hz, 3H). 13C NMR (126 MHz,
DMSO-d6) δ 161.07, 137.05, 133.42, 128.15, 126.36, 123.57, 120.59,
112.13, 102.70, 38.93, 31.79, 20.10, 14.20. HRMS, calcd for
C13H16ClN2O [M + H]
+: 251.0946, found 251.0947. HPLC: purity
99%, retention time 14.5 min.
4.2.22. 6-Chloro-N-pentyl-1H-indole-2-carboxamide (12e). The
product was obtained using general procedure 1 starting from 10. The
product was obtained as a light brown solid in 91% yield. 1HNMR (500
MHz, DMSO-d6) δ
1H NMR (500 MHz, DMSO-d6) δ: 11.69 (s, 1H),
7.51 (t, J = 6.0 Hz, 1H), 6.66 (d, J = 8.5 Hz, 1H), 7.43 (s, 1H), 7.14 (m,
1H), 7.03 (dd, J = 8.5, 2.0 Hz, 1H), 3.30 (q, J = 7.5 Hz, 2H), 1.57−1.53
(m, 2H), 1.24−1.20 (m, 4H), 0.92 (t, J = 7.5 Hz, 3H). 13C NMR (126
MHz, DMSO-d6) δ 161.05, 137.05, 133.42, 128.15, 126.35, 123.54,
120.55, 112.15, 102.72, 39.21, 29.36, 29.15, 22.36, 14.44. HRMS, calcd
for C14H18ClN2O [M + H]
+: 265.1102, found 265.1103. HPLC: purity
99%, retention time 14.3 min.
4.2.23. 6-Chloro-N-isopropyl-1H-indole-2-carboxamide (12f).
The product was obtained using general procedure 1 starting from
10. The product was obtained as a light brown solid in 84% yield. 1H
NMR (500 MHz, DMSO-d6) δ
1H NMR (500 MHz, DMSO-d6) δ:
11.67 (s, 1H), 8.30 (d, J = 8.0 Hz, 1H), 6.66 (d, J = 8.5 Hz, 1H), 7.43 (s,
1H), 7.14 (d, J = 2.0 Hz, 1H), 7.03 (dd, J = 8.5, 2.0 Hz, 1H), 4.17−4.09
(m, 1H), 1.20 (d, J = 6.5 Hz, 6H). 13C NMR (126 MHz, DMSO-d6) δ
160.28, 137.04, 133.50, 128.14, 126.33, 123.46, 120.56, 112.10, 102.88,
41.24, 41.14, 22.87. HRMS, calcd for C12H14ON2Cl [M + H]
+:
237.0789, found 237.0789. HPLC: purity 99%, retention time 10.8min.
4.2.24. 6-Chloro-N-cyclopropyl-1H-indole-2-carboxamide (12g).
The product was obtained using general procedure 1 starting from 10.
The product was obtained as a light brown solid in 91% yield. 1H NMR
(500 MHz, DMSO-d6) δ 11.70 (s, 1H), 8.54 (d, J = 2.0 Hz, 1H), 6.66
(d, J = 8.5 Hz, 1H), 7.43 (d, J = 2.0 Hz 1H), 7.12 (d, J = 2.0 Hz, 1H),
7.06 (dd, J = 8.5, 2.5 Hz, 1H), 2.90−2.83 (m, 1H). 0.75−0.71 (m, 2H),
0.61−0.55 (m, 2H). 13C NMR (126 MHz, DMSO-d6) δ 162.36,
137.09, 133.14, 128.24, 126.32, 123.54, 120.63, 112.16, 103.01, 23.12
(2×), 6.30. HRMS, calcd for C12H12ON2Cl [M +H]
+: 235.0633, found
235.0632. HPLC: purity 97%, retention time 11.8 min.
4.2.25. 6-Chloro-3-((dimethylamino)methyl)-N-propyl-1H-in-
dole-2-carboxamide (13). 6-Chloro-N-propyl-1H-indole-2-carboxa-
mide (12c) (50 mg, 0.20 mmol), dimethylamine (9.5 mg, 0.20 mmol),
paraformaldehyde (6.5 mg, 0.20 mmol), and 0.20 mL of acetic acid
were dissolved in 10 mL of MeOH. The reaction mixture was reﬂuxed
for 4 h. After completion, the product was puriﬁed by column
chromatography and eluted with 10% ethyl acetate in petroleum ether
as a solvent to obtain a white solid product with 91% yield. 1H NMR
(500 MHz, DMSO-d6) δ 11.75 (s, 1H), 10.53 (t, J = 2.0 Hz, 1H), 7.71
(d, J = 8.5 Hz, 1H), 7.43 (d, J = 2.0 Hz, 1H), 7.07 (dd, J = 8.5, 2.0 Hz,
1H), 3.69 (s, 2H), 3.29 (q, J = 6.5 Hz, 2H), 2.24 (s, 6H), 1.71−1.66 (m,
2H), 1.04 (t, J = 7.0 Hz, 3H). 13C NMR (126 MHz, DMSO-d6) δ
161.68, 135.54, 132.22, 128.27, 127.28, 121.36, 120.42, 112.11, 112.05,
52.57, 44.00, 43.97, 41.30, 22.75, 12.00. HRMS, calcd for
C15H21ON3Cl [M + H]
+: 294.1368, found 294.1367. HPLC: purity
99%, retention time 13.9 min.
4.2.26. General Synthetic Procedure 2: Hydrolysis Reaction. The
ester (1.0 equiv) was dissolved in THF (15 mL) while stirring. Then, a
solution of lithium hydroxide trihydrate (3.0 equiv) in demiwater (15
mL) was added and the mixture was stirred at 50 °C for 2 h.
Subsequently, the aqueous layer was extracted with EtOAc (3 × 15
mL). The combined organic layers were washed with brine, dried over
MgSO4, ﬁltered, and concentrated under reduced pressure. The crude
product 11 was used without further puriﬁcation.
4.2.27. (R)-6-Chloro-3-(3,7-dimethyloctanoyl)-N-propyl-1H-in-
dole-2-carboxamide (14). The product was obtained using general
procedures 1 and 2 starting from compounds Eleftheriaidis-14d and
12c. The product was obtained as a light brown solid in 65% yield over
two steps. 1H NMR (500 MHz, CDCl3) δ 11.83 (s, 1H), 11.45 (t, J =
2.0 Hz, 1H), 7.88 (d, J = 8.5 Hz, 1H), 7.33 (d, J = 2.0 Hz, 1H), 7.31 (dd,
J = 8.5, 2.5 Hz), 3.62 (q, J = 6.5 Hz, 2H), 3.06 (m, 2H), 2.28 (m, 1H),
1.83 (m, 2H), 1.56 (m, 1H), 1.42 (m, 2H), 1.33 (m, 2H), 1.22 (m, 2H),
1.12 (t, J = 7.5 Hz, 3H), 1.04 (d, J = 7.5 Hz, 3H), 0.89 (d, J = 7.5 Hz,
6H). 13C NMR (126 MHz, CDCl3) δ 199.61, 159.84, 136.61, 135.02,
130.45, 125.26, 123.66, 123.16, 115.54, 113.22, 51.18, 42.02, 39.08,
37.33, 29.61, 27.92, 24.79, 22.69, 22.62, 22.56, 20.01, 11.66. HRMS,
calcd for C22H32O2N2Cl [M + H]
+: 391.2147, found 391.2148. HPLC:
purity 97%, retention time 21.4 min.
4.2.28. (S)-6-Chloro-3-(3,7-dimethyloctanoyl)-N-propyl-1H-in-
dole-2-carboxamide (15). The product was obtained using general
procedures 1 and 2 starting from compounds Eleftheriaidis-14e and
12c. The product was obtained as a light brown solid in 55% yield over
two steps. 1H NMR (500 MHz, CDCl3) δ 11.63 (s, 1H), 11.41 (t, J =
2.0 Hz, 1H), 7.88 (d, J = 8.5 Hz, 1H), 7.71 (d, J = 2.0 Hz, 1H), 7.31 (dd,
J = 8.5, 2.5 Hz), 3.60 (q, J = 7.0Hz, 2H), 3.19−2.96 (m, 2H), 2.30−2.25
(m, 1H), 1.85−1.78 (m, 2H), 1.60−1.52 (m, 1H), 1.46−1.16 (m, 6H),
1.12 (t, J = 7.5 Hz, 3H), 1.04 (d, J = 6.5 Hz, 3H), 0.90 (d, J = 6.5 Hz,
6H). 13C NMR (126 MHz, CDCl3) δ 199.60, 159.81, 136.62, 134.97,
130.46, 125.27, 123.66, 123.17, 115.53, 113.18, 51.18, 42.00, 39.08,
37.32, 29.60, 27.92, 24.79, 22.69, 22.62, 22.56, 20.00, 11.66. HRMS,
calcd for C22H32O2N2Cl [M + H]
+: 391.2147, found 391.2149. HPLC:
purity 99%, retention time 22.9 min.
4.2.29. (E)-6-Chloro-N-ethyl-3-(3-((2-methoxybenzyl)amino)-3-
oxoprop-1-en-1-yl)-1H-indole-2-carboxamide (16). The product
was obtained using general procedures 1 and 2 starting from
compounds 9c and 11b. The product was obtained as a white solid
in 62% yield over two steps. 1HNMR (500MHz, DMSO-d6) δ 12.01 (s,
1H), 8.47 (t, J = 6.0 Hz, 1H), 8.31 (t, J = 6.0 Hz, 1H), 8.19 (d, J = 9.0
Hz, 1H), 8.02 (d, J = 7.5 Hz, 1H), 7.50 (s, 1H), 7.25 (m, 3H), 7.04 (d, J
= 7.5 Hz, 1H), 6.92 (t, J = 7.5 Hz, 1H), 6.89 (d, J = 9.0 Hz, 1H), 4.38 (d,
J = 6.0 Hz, 2H), 3.84 (s, 3H), 3.33 (m, 2H), 1.19 (t, J = 6.0 Hz, 3H). 13C
NMR (126MHz, DMSO-d6) δ 166.34, 161.31, 157.29, 136.87, 134.45,
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132.09, 129.02, 128.73, 127.32, 124.16, 123.14, 121.79, 120.79, 120.63,
113.16, 112.59, 111.05, 55.85, 37.93, 34.56, 31.15, 15.04. HRMS, calcd
for C22H23ClN3O3 [M+H]
+: 412.4122, found 412.4123. HPLC: purity
96%, retention time 13.8 min.
4.2.30. (E)-6-Chloro-3-(3-((2-methoxybenzyl)amino)-3-oxoprop-
1-en-1-yl)-N-propyl-1H-indole-2-carboxamide (17). The product
was obtained using general procedures 1 and 2 starting from
compounds 9c and 11c. The product was obtained as a white solid in
62% yield over two steps. 1H NMR (500 MHz, DMSO-d6) δ 12.03 (s,
1H), 8.47 (t, J = 5.5 Hz, 1H), 8.29 (t, J = 5.5 Hz, 1H), 8.07 (d, J = 16.0
Hz, 1H), 8.01 (d, J = 9.0 Hz, 1H), 7.52 (d, J = 2.0 Hz, 1H), 7.23 (m,
3H), 7.20 (dd, J = 7.5, 2.0 Hz, 1H), 6.94 (td, J = 6.5, 2.0 Hz, 1H), 6.90
(d, J = 16.0 Hz, 1H), 4.38 (d, J = 6.0 Hz, 2H), 3.86 (s, 3H), 3.28 (q, J =
6.0 Hz, 2H), 1.68 (m, 2H), 0.95 (t, J = 6.0 Hz, 3H). 13C NMR (126
MHz, DMSO-d6) δ 166.32, 161.45, 157.26, 136.87, 134.57, 132.07,
128.98, 128.69, 128.66, 127.30, 124.13, 123.12, 121.77, 120.73, 120.62,
113.06, 112.58, 111.03, 55.84, 41.44, 37.92, 22.72, 12.01. HRMS, calcd
for C23H25ClN3O3 [M+H]
+: 426.1579, found 426.1580. HPLC: purity
96%, retention time 13.8 min.
4.3. Human 15-LOX-1 Enzyme Inhibition Studies. The 15-
LOX-1 enzyme was expressed and puriﬁed as described before.46
Furthermore, the 15-LOX-1 enzyme activity studies were done using
procedures previously described by our group as well.30 15-LOX-1
activity was determined by the conversion of linoleic acid to
hydroperoxy-(9Z,11E)-octadecadienoic acid (λmax of 234 nm) in a
96-well plate. The conversion rate was followed by UV absorbance at
234 nm. The conversion rate was evaluated at the linear part of the plot,
and the substrate depletion covers the ﬁrst 16 min. The optimum
concentration of 15-LOX-1 was determined by an enzyme activity assay
and proved to be a 40-fold dilution. The assay buﬀer consists of 25 mM
N-(2-hydroxyethyl)piperazine-N′-ethanesulfonic acid titrated to pH
7.4. The substrate, linoleic acid (LA) (Sigma-Aldrich, L1376), was
dissolved in ethanol to a concentration of 500 nM. The absorbance
increased at 234 nm over time for the conversion of linoleic acid in the
presence (positive control) of the enzyme or remained constant in the
absence (blank control) of the enzyme.
To determine IC50 values, 140 μL of the inhibitors (0−71 μM, 2×
dilution series) was incubated with 50 μL of 1:40 enzyme solution for
10 min at room temperature in a 96-well plate. After 10 min incubation,
10 μL of 500 nMLAwas added to themixture, which resulted in desired
concentrations of the inhibitors (0−50 μM, 2× dilution series), a ﬁnal
dilution of the enzyme of 1:160, and 25 nM LA. The linear absorbance
increased in the absence of the inhibitor was set to 100%, whereas the
absorbance increased in the absence of the enzyme was set to 0%. All
experiments were performed at least in triplicate. The average values
and their standard deviations were plotted. Data analysis was performed
usingMicrosoft Excel professional plus 2013 and GraphPad Prism 5.01.
4.4. Cell Culture and MTS and RAW-Blue NF-κB Reporter
Gene Assays. RAW 264.7 murine macrophages were obtained from
ATCC (Wesel, Germany) and cultured in Dulbecco’s modiﬁed Eagle’s
medium + GlutaMAX (Gibco by Life Technologies, The Netherlands)
supplemented with 10% (v/v) fetal bovine serum and 100 U/mL 1%
penicillin/streptomycin (Gibco, The Netherlands) in a humidiﬁed 5%
CO2 atmosphere at 37 °C. RAW-Bluemacrophages were obtained from
InvivoGen (Toulouse, France) and cultured in the same conditions,
with the addition of 200 μg/mL Zeocin to the culture medium as
reported by the manufacturer.
RAW 264.7 cells were seeded at 5000 cells per well in a 96-well plate
1 day prior to the experiment. Cells were treated with 9c (i472) at 0.1,
1, 5, 10, and 50 μM for 48 h. The cell viability of the treated cells was
determined by adding 20 μL of the CellTiter reagent to each well. After
2 h incubation with the CelTiter reagent at 37 °C, the absorbance at 490
nm was measured using a Synergy H1 plate reader.
RAW-Blue cells were seeded at 10 × 104 cells per well in a 96-well
plate 1 day before the start of the experiment. Cells were treated with 9c
(i472) at 0.2, 1, and 5 μM and stimulated with 10 ng/mL LPS (Sigma-
Aldrich, The Netherlands) and 10 ng/mL IFNγ (Sigma-Aldrich, The
Netherlands) for 24 h. The secreted embryonic alkaline phosphatase
(SEAP) release was measured to monitor the NF-κB levels using the
QuantiBlue reagent (InvivoGen, Toulouse, France). After 2 h
incubation at 37 °C, the absorbance at 635−655 nm was measured
using a Synergy H1 plate reader according to the manufacturer’s
instructions.
4.5. LPS-Induced Cell Death. RAW 264.7 cells were seeded at
5000 cells per well in a 96-well plate. The ability of rescue was tested
with the treatment of 9c (i472) at 0.2, 1, and 5 μMor Zileuton at 5 μM
with 100 μg/mL LPS for 48 h. The cell viability was determined by the
MTS assay as described above.3
4.6. Gene Expression Analysis by Quantitative Reverse
Transcription Polymerase Chain Reaction (PCR). Total RNA
was isolated from RAW 264.7 cells using the SV total RNA isolation
system (Promega, Leiden, The Netherlands) according to the protocol
of the manufacturer. RNA integrity was determined by 28S/18S ratio
detection on an agarose gel, which was consistently found to be intact.
For gene expression analysis, RNA was reverse-transcribed using a
reverse-transcription kit (Promega). Subsequently, 10 ng of cDNA was
applied for each real-time PCR, which was performed on an ABI Prism
7900HT sequence detection system (Applied Biosystems, Nieuwerkerk
a/d IJssel, The Netherlands). The primers for NF-κB1 (Fw, 5′-
GAAATTCCTGATCCAGACAAAAAC-3′, Rv, 5′-ATCACTT-
CAATGGCCTCTGTGTAG-3′), NF-κB2 (Fw, 5′-CTGGTGGACA-
CATACAGGAAGAC-3′, Rv, 5′- ATAGGCACTGTCTTCTTT-
CACCTC-3′), RelA (Fw, 5′-CTTCCTCAGCCATGGTACCTCT-
3′, Rv, 5′- CAAGTCTTCATCAGCATCAAACTG-3′), RelB (Fw, 5′-
CTTTGCCTATGATCCTTCTGC-3′, Rv, 5′- GAGTCCAGTGA-
TAGGGGCTCT-3′) and iNOS (Fw, 5′-TATCAGGAAGAAATG-
CAGGAGAT-3′, Rv, 5′- GAGCACGCTGAGTACCTCATT-3′) were
purchased from Sigma. For each sample, the real-time PCR reactions
were performed in triplicate, and the averages of the obtained Ct values
were used for further calculations. Gene expression levels were
normalized to the expression of the reference gene glyceraldehyde-3-
phosphate dehydrogenase (GAPDH), which was not inﬂuenced by the
experimental conditions, resulting in the ΔCt value. Gene expression
levels were calculated by the comparative Ct method (2
−ΔΔCt).
4.7. Nitric Oxide (NO) Assay. The level of nitric oxide was
measured in RAW264.7 cells. Macrophage cells (2× 106 per well) were
seeded in six-well plates and incubated 24 h with or without 10 ng/mL
LPS (Sigma, The Netherlands) and 10 ng/mL IFNγ (Sigma-Aldrich,
The Netherlands) in the presence or absence of 5 μM 9c (i472). The
nitric oxide level in each sample was quantiﬁed using the commercially
available colorimetric nitric oxide assay kit (abcam, ab 65328, U.K.)
following the manufacturer’s instructions.
4.8. Lipid Peroxidation. RAW 264.7 cells were seeded into a six-
well plate containing 10× 106 cells per well. After overnight incubation,
cells were treated with 10 ng/mL LPS (Sigma, The Netherlands) and
10 ng/mL IFNγ (Sigma, The Netherlands) for 24 h in the presence or
absence of 5 μM PD146176, Zileuton, or 9c (i472), respectively. Cells
without LPS/IFNγ treatment were taken as a control. Lipid
peroxidation was detected by staining with BODIPY 581/591 C11
(Invitrogen, Karlsruhe, Germany) at a ﬁnal concentration of 2 mM for
30 min at 37 °C. The shift in ﬂuorescence from red to green was
analyzed by ﬂuorescence-activated cell sorting (FACS) using the Guava
Easy Cite 6-2L system (Merck Millipore, Darmstadt, Germany) by
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